How do we best measure the clinical benefit of a structure-modifying osteoarthritis drug?
Vignon
Eric P
EP
Claude Bernard University Lyon, Service de Rhumatologie, Centre Hospitalier Lyon-Sud,165 chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France. eric.vignon@chu-lyon.fr
Moreland
Larry
L
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D006801:Humans; D010003:Osteoarthritis / Q000188:drug therapy*; D012107:Research Design; D016896:Treatment Outcome
D018501:Antirheumatic Agents